Multidrug resistance (MDR) of tumour cells is considered to be one of the major obstacles to effective cancer chemotherapy (Curt et al., 1984; Bradley et al., 1988; van der Bliek & Borst, 1989) . Such resistance can be an intrinsic property of a tumour or may be acquired following courses of chemotherapy. MDR has been shown to be associated with reduced intracellular drug content due to the over-expression of the P-glycoprotein (P-170), an energy dependent efflux pump that prevents intracellular accumulation of antineoplastic drugs (Juliano & Ling, 1976) .
Since many mechanisms for the development of MDR are associated with energy metabolism pathways, the high aerobic glycolysis rate showed by resistant cells (Lyon et al., 1988; Kaplan et al., 1990) could make them targets for drugs inhibiting the energy metabolism.
Lonidamine (LND, Angelini ACRAF, Pomezia, Rome, Italy), a dichlorinated derivative of indazole-3-carboxylic acid, has been proven to strongly influence the energy metabolism of neoplastic cells inhibiting their aerobic lactate production (Floridi & Lehninger, 1983 ). LND appears also to be able to induce wide changes in plasma membrane due to its high affinity for the inner leaflet of the lipid bilayer (Malorni et al., 1988) . Both the main LND effects, the reduction of ATP production and the membrane damage, could impair the metabolic adaptations associated with the development of drug resistance.
Previous data obtained in our laboratory demonstrated that LND differently affected the cell survival of melanoma lines and when used in combination with ADR determined a synergistic effect, according to the sequence employed (Zupi et al., 1986) . Recently, it was reported that LND also enhanced the cytotoxic effect of cis-platinum on a human squamous cell carcinoma (Raaphorst et al., 1990) . Moreover, when combined with radiation LND potentiates the lethal effect of ionising radiation on fibrosarcoma tumour cells (Kim et al., 1984) .
In the present study we (ICy, value) . Samples from cells exposed for different times to ADR or to ADR + LND were twice washed in PBS and kept frozen (106 cells ml-') for intracellular ADR determination.
Purified specific anti-ADR IgGs from polyclonal anti-ADR immune serum were employed to determine the intracellular ADR content as previously described (Citro et al., 1988) . Briefly, the assay was performed by a competitive ELISA using a suspension from treated cells in cold PBS (106 cells ml-' sonicated at 100 W for 1 min). Experimental data were compared using Student's t-test, and the results were considered statistically significant when P <0.05.
The sensitivity of both cell lines to ADR and to ADR + LND exposures is reported in Table I On the contrary, the ADR + LND association strongly affected the intracellular ADR accumulation of the resistant cells. In fact, the presence of LND nearly allowed to double the intracellular ADR content for all doses and exposure times employed. The differences of intracellular ADR level detected between the two treatments came out highly significant from the statistical analysis (A, B, C, D vs Al, B1, Cl, D1; Table III ).
Comparing the data reported in Tables II and III , it appears that the combination allowed ADR to achieve in the resistant cells an intracellular amount similar to that obtained for the wild type cells, indicating that LND had the ability to restore the in vitro sensitivity of ADR-resistant cells. In particular, LND allows ADR to reach the same intracellular content otherwise achievable with a 1,000-fold higher ADR dose given as single agent (Table III) . The values of cell survival demonstrate the ability 'of LND to overcome ADR resistance (Table III) . This effect is particularly relevant since at the lowest ADR dose, uneffective on the resistant cells, the combination determines a remarkable increase in cell lethality. In conclusion, these results indicate that the combination ADR + LND could be useful to improve the therapeutic index of ADR treatment.
The enhancement of the ADR cytotoxicity observed on the MCF-7 ADRR cells could be the result of two simultaneous selective LND effects: (1) the LND-lipid bilayer interactions give rise to clustering of intrinsic intramembrane proteins like P-170 glycoprotein, which is present on the MCF-7 ADRR cell membranes (Fairchild et al., 1987) , impairing its biological functions and thus reducing drug efflux and detoxification; (2) Lonidamine specifically inhibits the activity of mitochondria bound hexokinase (Floridi et al., 1989) affecting the aerobic glycolysis of tumour cells. Since ADRR cells show an enhanced rate of glycolysis (3-fold), as compared to drug sensitive cells (Kaplan et al., 1990) , LND could selectively impair cellular energy-dependent mechanisms like drug efflux, drug-conjugation, enzyme synthesis, and lethal damage recovery. Table II Intracellular The relationship between the high rate of aerobic glycolysis and drug resistance of MCF-7 ADRR cells was recently demonstrated by Kaplan et al. using 2-deoxyglucose, a specific glycolysis inhibitor. This drug was found to be extremely toxic for the cells which had acquired resistance to Adriamycin (Kaplan et al., 1990) . These data are in agreement with our results, demonstrating that a specific inhibitor of aerobic glycolysis like Lonidamine can play a remarkable role to reduce or overcome multidrug resistance.
In conclusion, the present study indicates the possibility to use Lonidamine as potentiating agent to interfere with MDR properties. Considering its good tolerance reported in preliminary clinical trials (Ozols et al., 1983; Evans et al., 1984; Pronzato et al., 1989) Lonidamine, in combination with antitumour drugs, could improve cancer therapy when tumours initially responsive to chemotherapy develop resistance to the drugs following treatment with one of them.
